Phreesia's Network Solutions Business Attracts Mizuho's Outperform Rating
ByAinvest
Wednesday, Aug 27, 2025 2:20 pm ET1min read
PHR--
Valiquette underscores that the network solutions business has been a key driver for Phreesia's EBITDA margins, which have improved to +18-19% in 2025. He expects further enhancements in the company's EBITDA margins, with a potential +15-20% compound annual growth rate (CAGR) in network solutions revenue. The analyst has set a $36 per share target on the stock, noting that Phreesia currently trades at a nearly 14x enterprise value (EV)/EBITDA multiple for 2026 estimates, compared to an average multiple of ~17x among its healthcare tech peers.
The Mizuho analyst's recommendation underscores the growing demand for patient engagement solutions and Phreesia's ability to leverage its network solutions business to drive revenue acceleration. Investors should closely monitor Phreesia's financial performance and the continued growth prospects of its network solutions business.
References:
[1] https://seekingalpha.com/news/4489705-phreesia-stock-new-outperform-mizuho
Phreesia, a patient intake management software developer, has seen its stock rise after Mizuho launched coverage with an Outperform recommendation. The recommendation is based on potential in the company's network solutions business, which generated $121.6M in revenue for 2022. Mizuho expects Phreesia's network solutions business to continue to grow, driven by increasing demand for patient engagement solutions.
Phreesia (NYSE: PHR), a developer of patient intake management software, experienced a significant stock rise following Mizuho's launch of its coverage with an Outperform recommendation. The recommendation is centered on the company's network solutions business, which generated $121.6 million in revenue for 2022 [1]. Mizuho analyst Steven Valiquette highlighted the potential of this business, which provides patients with customized health content and allows Phreesia to capitalize on pharma digital marketing expenditure. The network solutions business has demonstrated robust growth, with revenue increasing by ~29% year-over-year (YoY) in 2025 compared to ~27% YoY growth in 2024.Valiquette underscores that the network solutions business has been a key driver for Phreesia's EBITDA margins, which have improved to +18-19% in 2025. He expects further enhancements in the company's EBITDA margins, with a potential +15-20% compound annual growth rate (CAGR) in network solutions revenue. The analyst has set a $36 per share target on the stock, noting that Phreesia currently trades at a nearly 14x enterprise value (EV)/EBITDA multiple for 2026 estimates, compared to an average multiple of ~17x among its healthcare tech peers.
The Mizuho analyst's recommendation underscores the growing demand for patient engagement solutions and Phreesia's ability to leverage its network solutions business to drive revenue acceleration. Investors should closely monitor Phreesia's financial performance and the continued growth prospects of its network solutions business.
References:
[1] https://seekingalpha.com/news/4489705-phreesia-stock-new-outperform-mizuho

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet